Spravato in Turkey
How patients in Turkey access Spravato (esketamine nasal) via Named Patient Program.
Spravato - overview
Spravato (esketamine nasal) is manufactured by Janssen (J&J) and indicated for Treatment-resistant depression — OUT OF SCOPE (esketamine, DEA Schedule III + REMS in-clinic only; PlatformCo does not handle controlled substances. Also practically infeasible given REMS site-of-care restriction.). It is a unverified approved by the US FDA in unverified and may be accessible to patients in Turkey through a Named Patient Program or personal-import pathway.
Access in Turkey
Turkey's TITCK operates a named-patient program; HCPs coordinate with Turkish Pharmacists' Association.
How Reserve Meds coordinates access in Turkey
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Turkey-specific eligibility.
- Treating physician in Turkey issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Spravato from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Turkey.
Typical timeline for Turkey
End-to-end, most requests are completed in 2-6 weeks. Turkey's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Turkey ask
- Is the pathway legal in Turkey? Yes - it operates under Turkey's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Turkey able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.